Pfizer's sickle cell drug fails main goal in late-stage trial
Aug 15 (Reuters) - Pfizer PFE.N said on Friday that its experimental sickle cell disease drug failed to meet the main goal in a late stage trial in patients 16 years of age and older.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
US-Iran Truce, Gold Prices Return to $4,800, Is Now Still the Time to Buy?

DRAM ETF Surges Over 18% in Overnight Trading, Is It Worth Investing?

Why Meta Stock Jumped Today — And Whether 2026 Is Still a Time to Buy

Anthropic Claude Mythos Preview Sparks Wall Street Panic: Bessent, Powell Summon CEOs; Cloudflare Tumbles 8%

What is the CLARITY Act? 2026 Guide to US Crypto Regulation and Stablecoin Yield Rules

Tradingkey






